JP2019527555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527555A5 JP2019527555A5 JP2019505220A JP2019505220A JP2019527555A5 JP 2019527555 A5 JP2019527555 A5 JP 2019527555A5 JP 2019505220 A JP2019505220 A JP 2019505220A JP 2019505220 A JP2019505220 A JP 2019505220A JP 2019527555 A5 JP2019527555 A5 JP 2019527555A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- amino acids
- polypeptide chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 254
- 150000001413 amino acids Chemical class 0.000 claims 125
- 229920001184 polypeptide Polymers 0.000 claims 110
- 102000004196 processed proteins & peptides Human genes 0.000 claims 110
- 108090000765 processed proteins & peptides Proteins 0.000 claims 110
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 9
- 238000003259 recombinant expression Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021199878A JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| US62/369,883 | 2016-08-02 | ||
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199878A Division JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527555A JP2019527555A (ja) | 2019-10-03 |
| JP2019527555A5 true JP2019527555A5 (https=) | 2020-09-10 |
| JP6993402B2 JP6993402B2 (ja) | 2022-02-03 |
Family
ID=59564253
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505220A Active JP6993402B2 (ja) | 2016-08-02 | 2017-07-31 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2021199878A Active JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A Active JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A Pending JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199878A Active JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A Active JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A Pending JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10611816B2 (https=) |
| EP (2) | EP3494133B1 (https=) |
| JP (4) | JP6993402B2 (https=) |
| KR (1) | KR102527052B1 (https=) |
| CN (2) | CN109790211B (https=) |
| AU (3) | AU2017306038B2 (https=) |
| CY (1) | CY1125601T1 (https=) |
| DK (1) | DK3494133T3 (https=) |
| ES (1) | ES2928051T3 (https=) |
| HR (1) | HRP20221183T1 (https=) |
| HU (1) | HUE060121T2 (https=) |
| IL (2) | IL264425B2 (https=) |
| LT (1) | LT3494133T (https=) |
| PL (1) | PL3494133T3 (https=) |
| PT (1) | PT3494133T (https=) |
| RS (1) | RS63615B1 (https=) |
| SG (2) | SG10201913959WA (https=) |
| SI (1) | SI3494133T1 (https=) |
| SM (1) | SMT202200379T1 (https=) |
| WO (1) | WO2018026691A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221183T1 (hr) * | 2016-08-02 | 2022-12-09 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | T-stanični receptori anti-kras-g12d |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| KR20250037592A (ko) | 2017-09-20 | 2025-03-17 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체 |
| AU2018345400B2 (en) | 2017-10-05 | 2024-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| WO2020154617A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| CN114026116A (zh) * | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| CN115151274B (zh) * | 2019-11-05 | 2026-03-27 | 得克萨斯州大学系统董事会 | Hla限制性hormad1 t细胞受体及其用途 |
| BR112022011795A2 (pt) | 2019-12-20 | 2022-08-30 | Instil Bio Uk Ltd | Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos |
| KR102842684B1 (ko) * | 2019-12-30 | 2025-08-05 | 브리스타 이뮤노테크 리미티드 | 향상된 t-세포 수용체 star 및 이의 적용 |
| US20240294598A1 (en) * | 2020-05-25 | 2024-09-05 | China Immunotech (Beijing) Biotechnology Co., Ltd | Enhanced synthetic t-cell receptor and antigen receptor |
| EP4178976A1 (en) * | 2020-07-13 | 2023-05-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class ii?restricted drb t cell receptors against ras with g12d mutation |
| TW202229327A (zh) * | 2020-10-02 | 2022-08-01 | 美國衛生與公眾服務部 | 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體 |
| EP4247401A4 (en) * | 2020-11-20 | 2025-06-11 | Think Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR OPTIMIZED PEPTIDE VACCINES |
| WO2022115641A2 (en) * | 2020-11-25 | 2022-06-02 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| US20260021183A1 (en) * | 2022-07-22 | 2026-01-22 | Board Of Regents, The University Of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
| CN115850444B (zh) * | 2022-09-15 | 2025-01-28 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117777270B (zh) * | 2022-09-29 | 2025-04-25 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
| CN120693174A (zh) * | 2022-12-13 | 2025-09-23 | 百欧恩泰美国公司 | T细胞受体构建体及其用途 |
| AU2024309123A1 (en) | 2023-06-28 | 2026-01-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| CN120157754A (zh) * | 2023-12-14 | 2025-06-17 | 新景智源生物科技(苏州)有限公司 | Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
| WO2025259799A2 (en) * | 2024-06-12 | 2025-12-18 | Biontech Us Inc. | T cell receptor compositions and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| WO2008089053A2 (en) | 2007-01-12 | 2008-07-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| HRP20171164T1 (hr) | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| AU2012309830B2 (en) | 2011-09-15 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage |
| WO2013081188A1 (ja) * | 2011-11-30 | 2013-06-06 | 独立行政法人国立がん研究センター | 誘導悪性幹細胞 |
| TN2015000444A1 (en) * | 2013-06-03 | 2017-04-06 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| CN118994363A (zh) | 2014-11-26 | 2024-11-22 | 美国卫生和人力服务部 | 抗突变的kras的t细胞受体 |
| ES2879287T3 (es) * | 2015-09-15 | 2021-11-22 | Us Health | Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8 |
| HRP20221183T1 (hr) * | 2016-08-02 | 2022-12-09 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | T-stanični receptori anti-kras-g12d |
| AU2024309123A1 (en) | 2023-06-28 | 2026-01-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
-
2017
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en not_active Ceased
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 SM SM20220379T patent/SMT202200379T1/it unknown
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active Active
- 2017-07-31 IL IL301894A patent/IL301894B2/en unknown
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2022
- 2022-09-29 CY CY20221100645T patent/CY1125601T1/el unknown
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125B2/en active Active
- 2023-12-27 JP JP2023221526A patent/JP7649370B2/ja active Active
-
2024
- 2024-01-25 US US18/423,020 patent/US12391742B2/en active Active
-
2025
- 2025-03-07 JP JP2025036871A patent/JP2025090690A/ja active Pending
- 2025-07-15 US US19/269,450 patent/US20250340611A1/en active Pending
-
2026
- 2026-01-15 AU AU2026200276A patent/AU2026200276A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527555A5 (https=) | ||
| HRP20221183T1 (hr) | T-stanični receptori anti-kras-g12d | |
| JP2020534828A5 (https=) | ||
| Walker et al. | Yeast eIF4B binds to the head of the 40S ribosomal subunit and promotes mRNA recruitment through its N-terminal and internal repeat domains | |
| Mo et al. | Targeting Ubc9 for cancer therapy | |
| KR20200033952A (ko) | 신규 융합 단백질의 제조 및 이의 단백질 합성 향상에서의 응용 | |
| Fournier et al. | Recruitment of RED-SMU1 complex by Influenza A Virus RNA polymerase to control Viral mRNA splicing | |
| CN100400657C (zh) | 磷酸激酶及其应用 | |
| JP2011188853A5 (https=) | ||
| JP2015535816A5 (https=) | ||
| JP2018141797A5 (https=) | ||
| Akiyama et al. | cDNA cloning of a new putative ATPase subunit p45 of the human 26S proteasome, a homolog of yeast transcriptional factor Sug1p | |
| Xu et al. | Sug1 modulates yeast transcription activation by Cdc68 | |
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN | |
| Mishra et al. | mRNA recruiting eIF4 factors involved in protein synthesis and its regulation | |
| Auvray et al. | HOXC4 homeoprotein efficiently expands human hematopoietic stem cells and triggers similar molecular alterations as HOXB4 | |
| Yan et al. | SUMOylation of W or1 by a novel SUMO E 3 ligase controls cell fate in C andida albicans | |
| Zaccheo et al. | Kinetics of insulin-like growth factor II (IGF-II) interaction with domain 11 of the human IGF-II/mannose 6-phosphate receptor: function of CD and AB loop solvent-exposed residues | |
| JP2020127419A5 (https=) | ||
| CN104193826B (zh) | 一种融合多肽及其在制备抗肿瘤药物中的应用 | |
| CN103255113B (zh) | 一种发形霞水母过氧化物还原酶及其编码基因与应用 | |
| CN103665141B (zh) | 与艰难梭菌细胞毒素b相互作用的蛋白 | |
| CN107164474B (zh) | 一种检测calr基因2型突变的引物组合物及试剂盒 | |
| Yang et al. | Ubl4b, an X-derived retrogene, is specifically expressed in post-meiotic germ cells in mammals | |
| JP2017525357A5 (https=) |